Elaprase Shire plc - Treatment for Hunter Syndrome
Elaprase is a purified form of the human lysosomal enzyme iduronate-2-sulfatase produced by recombinant DNA technology. Elaprase is indicated for the treatment of Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II).Posted: July 2006
Related Articles:
- Shire Provides Update on U.S. Marketing Application of Elaprase - May 17, 2006
- Shire Files Elaprase (idursulfase) With the FDA for the Treatment of Hunter Syndrome - November 24, 2005
Elaprase (idursulfase) FDA Approval History
